Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Drugs And Therapeutic Biologics Approved In 2016

Executive Summary

Interactive chart of 2016 novel approvals from US FDA's Center for Drug Evaluation and Research.

FDA's Center for Drug Evaluation and Research approved 22 new molecular entities and novel therapeutic biologics in 2016.

The approvals chart below can be searched and sorted. Click on a column header to sort by that parameter, including sponsor, approval date, indication, and designations. Use the "search" box to filter the data. Searching by "priority" or "orphan," for example, will display only priority review or orphan drug approvals. To keep the size of the chart in check, breakthrough therapy designations are listed as "BTD" and products approved under accelerated approval regulations are designated "AA."

The Pink Sheet keeps ongoing track of new drug and therapeutic biologic approvals on the FDA Performance Tracker's Novel CDER Approvals page.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS119756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel